Vera Therapeutics (NASDAQ: VERA) is gaining traction after releasing data on its lead drug, atacicept, for IgA nephropathy (IgAN). With limited treatments available for this chronic kidney disease, the company’s clinical results have drawn attention from analysts and investors alike.

On January 27, Goldman Sachs analyst Paul Choi initiated coverage with a Buy rating and a $58 price target, implying a 61 percent upside from Vera’s price at the time. The call was based on strong Phase II data and the potential for atacicept to become a best-in-class option for treating IgAN.

Clinical Results Signal Serious Potential

Atacicept targets Gd-IgA1, a key disease driver in IgAN. Vera’s most recent trial showed clear improvements across multiple measures:

• 66 percent reduction in galactose-deficient IgA1 (Gd-IgA1)
• 75 percent resolution of hematuria
• 52 percent reduction in proteinuria
• Minimal decline in eGFR, a key marker of kidney function

These numbers suggest the drug may be modifying the disease, not just managing symptoms. That matters in a space where treatment has long focused on slowing decline rather than reversing course.

Market Reaction Reflects Rising Confidence

Vera’s stock rose to $38.11 on February 5, following the Goldman upgrade. The move confirms growing interest, but several analysts still believe the stock trades below its intrinsic value. With Phase III trials underway, investors are watching for confirmation that the early data can hold in a larger, longer-term study.

Buyout Speculation Is Picking Up

Given atacicept’s profile and late-stage development, Vera is increasingly seen as a potential acquisition target. Big Pharma has been active in the kidney and autoimmune spaces, and Vera offers a clear entry point with a differentiated asset.

Rivals Calliditas (Tarpeyo) and Travere Therapeutics (Filspari) already have approved therapies for IgAN, but atacicept’s broader efficacy could position it above both if it continues to deliver.